125 related articles for article (PubMed ID: 12845959)
1. Effective treatment of disseminated peritoneal colon cancer with new replication-competent herpes simplex viruses.
Kimata H; Takakuwa H; Goshima F; Teshigahara O; Nakao A; Kurata T; Sata T; Nishiyama Y
Hepatogastroenterology; 2003; 50(52):961-6. PubMed ID: 12845959
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10.
Watanabe D; Goshima F; Mori I; Tamada Y; Matsumoto Y; Nishiyama Y
J Dermatol Sci; 2008 Jun; 50(3):185-96. PubMed ID: 18226503
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic viral therapy for breast cancer with herpes simplex virus type 1 mutant HF 10.
Teshigahara O; Goshima F; Takao K; Kohno S; Kimata H; Nakao A; Nishiyama Y
J Surg Oncol; 2004 Jan; 85(1):42-7. PubMed ID: 14696086
[TBL] [Abstract][Full Text] [Related]
4. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
[TBL] [Abstract][Full Text] [Related]
5. Herpes simplex virus type 1 mutant HF10 oncolytic viral therapy for bladder cancer.
Kohno S; Luo C; Goshima F; Nishiyama Y; Sata T; Ono Y
Urology; 2005 Nov; 66(5):1116-21. PubMed ID: 16286150
[TBL] [Abstract][Full Text] [Related]
6. Enhanced efficacy of herpes simplex virus mutant HF10 combined with paclitaxel in peritoneal cancer dissemination models.
Shimoyama S; Goshima F; Teshigahara O; Kasuya H; Kodera Y; Nakao A; Nishiyama Y
Hepatogastroenterology; 2007 Jun; 54(76):1038-42. PubMed ID: 17629034
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice.
Takakuwa H; Goshima F; Nozawa N; Yoshikawa T; Kimata H; Nakao A; Nawa A; Kurata T; Sata T; Nishiyama Y
Arch Virol; 2003 Apr; 148(4):813-25. PubMed ID: 12664303
[TBL] [Abstract][Full Text] [Related]
8. Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer.
Kimata H; Imai T; Kikumori T; Teshigahara O; Nagasaka T; Goshima F; Nishiyama Y; Nakao A
Ann Surg Oncol; 2006 Aug; 13(8):1078-84. PubMed ID: 16865590
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus.
Kohno SI; Luo C; Nawa A; Fujimoto Y; Watanabe D; Goshima F; Tsurumi T; Nishiyama Y
Cancer Gene Ther; 2007 Nov; 14(11):918-26. PubMed ID: 17693992
[TBL] [Abstract][Full Text] [Related]
10. [Novel treatment with oncolytic herpes simplex virus, 'HF10' against breast cancer].
Kimata H; Teshigahara O; Nishiyama Y; Nakao A
Nihon Rinsho; 2004 May; 62(5):987-93. PubMed ID: 15148832
[TBL] [Abstract][Full Text] [Related]
11. An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma.
Yoon SS; Nakamura H; Carroll NM; Bode BP; Chiocca EA; Tanabe KK
FASEB J; 2000 Feb; 14(2):301-11. PubMed ID: 10657986
[TBL] [Abstract][Full Text] [Related]
12. Enhanced efficacy of conditionally replicating herpes simplex virus (G207) combined with 5-fluorouracil and surgical resection in peritoneal cancer dissemination models.
Nakano K; Todo T; Zhao G; Yamaguchi K; Kuroki S; Cohen JB; Glorioso JC; Tanaka M
J Gene Med; 2005 May; 7(5):638-48. PubMed ID: 15754306
[TBL] [Abstract][Full Text] [Related]
13. Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy.
Coukos G; Makrigiannakis A; Montas S; Kaiser LR; Toyozumi T; Benjamin I; Albelda SM; Rubin SC; Molnar-Kimber KL
Cancer Gene Ther; 2000 Feb; 7(2):275-83. PubMed ID: 10770637
[TBL] [Abstract][Full Text] [Related]
14. Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells.
Taneja S; MacGregor J; Markus S; Ha S; Mohr I
Proc Natl Acad Sci U S A; 2001 Jul; 98(15):8804-8. PubMed ID: 11438715
[TBL] [Abstract][Full Text] [Related]
15. Treatment of solid sarcomas in immunocompetent mice with novel, oncolytic herpes simplex viruses.
Sugiura S; Goshima F; Takakuwa H; Sata T; Nakashima T; Nishiyama Y
Otolaryngol Head Neck Surg; 2004 Apr; 130(4):470-8. PubMed ID: 15100647
[TBL] [Abstract][Full Text] [Related]
16. Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer.
Coukos G; Makrigiannakis A; Kang EH; Caparelli D; Benjamin I; Kaiser LR; Rubin SC; Albelda SM; Molnar-Kimber KL
Clin Cancer Res; 1999 Jun; 5(6):1523-37. PubMed ID: 10389942
[TBL] [Abstract][Full Text] [Related]
17. Effect of preexisting anti-herpes immunity on the efficacy of herpes simplex viral therapy in a murine intraperitoneal tumor model.
Lambright ES; Kang EH; Force S; Lanuti M; Caparrelli D; Kaiser LR; Albelda SM; Molnar-Kimber KL
Mol Ther; 2000 Oct; 2(4):387-93. PubMed ID: 11020355
[TBL] [Abstract][Full Text] [Related]
18. Oncolysis by viral replication and inhibition of angiogenesis by a replication-conditional herpes simplex virus that expresses mouse endostatin.
Mullen JT; Donahue JM; Chandrasekhar S; Yoon SS; Liu W; Ellis LM; Nakamura H; Kasuya H; Pawlik TM; Tanabe KK
Cancer; 2004 Aug; 101(4):869-77. PubMed ID: 15305421
[TBL] [Abstract][Full Text] [Related]
19. Combination treatment of human pancreatic cancer xenograft models with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib and oncolytic herpes simplex virus HF10.
Yamamura K; Kasuya H; Sahin TT; Tan G; Hotta Y; Tsurumaru N; Fukuda S; Kanda M; Kobayashi D; Tanaka C; Yamada S; Nakayama G; Fujii T; Sugimoto H; Koike M; Nomoto S; Fujiwara M; Tanaka M; Kodera Y
Ann Surg Oncol; 2014 Feb; 21(2):691-8. PubMed ID: 24170435
[TBL] [Abstract][Full Text] [Related]
20. Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene.
Pawlik TM; Nakamura H; Mullen JT; Kasuya H; Yoon SS; Chandrasekhar S; Chiocca EA; Tanabe KK
Cancer; 2002 Sep; 95(5):1171-81. PubMed ID: 12209705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
